Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Civica’s $27.8m New Facility Expands Virginia Drug Hub Vision

Meanwhile, CivicaScript Targets Prostate Cancer With First Product Launch

Executive Summary

Civica has announced a further $27.8m investment to support its plans for insulin and other essential medicines. The news comes shortly after CivicaScript announced its first launch in the form of abiraterone tablets.

You may also be interested in...



Civica Adds New Partners To Access Initiatives

Civica has selected Profil as its clinical partner as it develops its affordable range of biosimilar insulins, and has also added pharmacy benefit manager EmsanaRx to its generic CivicaScript network.

Civica Takes First Foray Into Biosimilars With GeneSys Insulins Partnership

Non-profit generics firm Civica is partnering with GeneSys Biologics to make affordable biosimilars of Lantus, Humalog and Novolog for the US market, which it aims to sell at $30 a vial or $55 per pack of cartridges.

Civica Takes On The Challenge Of Insulin Affordability

The non-profit organization plans to make biosimilar versions of Lantus, Humalog and Novolog and sell them for no more than $30/vial.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB152169

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel